Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 764524

Next Previous
Drug Profile

BI 764524

Alternative Names: BI-764524

Latest Information Update: 25 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antibodies; Eye disorder therapies; Immunotherapies
  • Mechanism of Action Semaphorin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diabetic retinopathy

Most Recent Events

  • 20 Mar 2024 Boehringer Ingelheim plans a phase II CRIMSON trial for Diabetic retinopathy (In adults, In the elderly) in the US in May 2024 (Intravitreous, Injection) (NCT06321302)
  • 28 Apr 2023 Boehringer Ingelheim completes a phase I/II HORNBILL trial in Diabetic retinopathy in USA (NCT04424290)
  • 12 Jun 2020 Phase-I/II clinical trials in Diabetic retinopathy in USA (Intravitreous) (NCT04424290)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top